Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

-0.08 (-2.14%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
79,239 shs
Average Volume
199,855 shs
Market Capitalization
$219.29 million
P/E Ratio
Dividend Yield
Price Target

Acumen Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
228.8% Upside
$12.00 Price Target
Short Interest
2.09% of Float Sold Short
Dividend Strength
News Sentiment
0.44mentions of Acumen Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.21) to ($1.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

322nd out of 914 stocks

Biological Products, Except Diagnostic Industry

44th out of 153 stocks

ABOS stock logo

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ABOS Stock Price History

ABOS Stock News Headlines

Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
See More Headlines
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.36 per share


Free Float
Market Cap
$219.29 million
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Daniel J. O'Connell M.B.A. (Age 53)
    CEO & Director
    Comp: $901.2k
  • Mr. Matt Zuga
    CFO & Chief Business Officer
  • Mr. Derek M. Meisner Esq. (Age 53)
    J.D., Chief Legal Officer & Corporate Secretary
    Comp: $240.17k
  • Dr. James Doherty Ph.D. (Age 56)
    President & Chief Development Officer
  • Dr. Grant A. Krafft Ph.D.
  • Dr. Caleb E. Finch Ph.D.
  • Dr. William L. Klein Ph.D.
  • Mr. Russell Barton M.S. (Age 65)
    Chief Operating Officer
    Comp: $223.68k
  • Ms. Kelly Carranza
    Vice President, Finance & Accounting and Corporate Controller
  • Ms. Alex Braun M.B.A.
    VP & Head of Investor Relations

ABOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings
or view top-rated stocks.

What is Acumen Pharmaceuticals' stock price target for 2024?

4 brokers have issued twelve-month target prices for Acumen Pharmaceuticals' stock. Their ABOS share price targets range from $8.00 to $15.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 228.8% from the stock's current price.
View analysts price targets for ABOS
or view top-rated stocks among Wall Street analysts.

How have ABOS shares performed in 2024?

Acumen Pharmaceuticals' stock was trading at $3.84 at the beginning of the year. Since then, ABOS stock has decreased by 4.9% and is now trading at $3.65.
View the best growth stocks for 2024 here

When is Acumen Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ABOS earnings forecast

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.29).

What ETF holds Acumen Pharmaceuticals' stock?

iShares Neuroscience and Healthcare ETF holds 2,998 shares of ABOS stock, representing 0.28% of its portfolio.

When did Acumen Pharmaceuticals IPO?

Acumen Pharmaceuticals (ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.77%), Price T Rowe Associates Inc. MD (1.83%), Ikarian Capital LLC (0.44%), Susquehanna Fundamental Investments LLC (0.10%), SG Americas Securities LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel Joseph Oconnell, Derek M Meisner, Jeffrey L Ives, John A Stalfort III, Marc Benioff, Matt Zuga, Nathan B Fountain, Paul B Manning, Ra Capital Management, LP, Russell Barton and Sands Capital Global Venture F.
View institutional ownership trends

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABOS) was last updated on 5/19/2024 by Staff

From Our Partners